{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-029705","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.045629+00:00","generated_at":"2026-05-16T06:22:26.971373+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kura Oncology amends bylaws to update advance notice, quorum, indemnification provisions","bullets":["Updated advance notice: annual meeting date shift threshold extended to >70 days (previously 30) before alternative notice window applies.","Quorum threshold changed from majority of outstanding shares to majority of voting power; default approval changed to majority of votes cast.","Incorporated universal proxy rules (Rule 14a-19); limited shareholder nominations to number of directors to be elected, no substitute nominees.","Enhanced forum selection: Delaware federal courts as backup for state court actions; added exclusive forum for Securities Act claims.","Expanded mandatory indemnification for directors/officers to maximum extent allowed by law; added expense advancement procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-029705","json":"https://secwatch.observer/filing/0001193125-26-029705.json","markdown":"https://secwatch.observer/filing/0001193125-26-029705.md","text":"https://secwatch.observer/filing/0001193125-26-029705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/d18498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:22:26.971373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db1ea66c9ef2bd710a9d1b01e31577b92b49ca7a","claim":"Kura Oncology, Inc.: The Board adopted amended and restated bylaws effective January 28, 2026, making numerous changes to stockholder meeting procedures, advance notice requirements, quorum and voting thresholds, and other governance provisions (effective 2026-01-28).","evidence_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001628280-26-039465","ticker":"IOT","company_name":"Samsara Inc.","filed_at":"2026-06-01T20:07:41+00:00","headline":"Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026","event_type":"other_material","sec_items":["3.03","5.03","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039465","json":"https://secwatch.observer/filing/0001628280-26-039465.json","markdown":"https://secwatch.observer/filing/0001628280-26-039465.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/iot-20260601.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm"}},{"accession":"0000001961-26-000006","ticker":null,"company_name":"WORLDS INC","filed_at":"2026-06-01T18:59:55+00:00","headline":"Worlds Inc. changes name to Gemaxel Inc., effective March 26, 2026","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000001961-26-000006","json":"https://secwatch.observer/filing/0000001961-26-000006.json","markdown":"https://secwatch.observer/filing/0000001961-26-000006.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/0000001961-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/wddd8k052826.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"On March 26, 2026 the Company amended ARTICLE FIRST of its Certificate of Incorporation and changed its name to Gemaxel Inc. from Worlds Inc.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1961/000000196126000006/0000001961-26-000006-index.htm"}},{"accession":"0001493152-26-026548","ticker":"BTCS","company_name":"BTCS Inc.","filed_at":"2026-06-01T13:29:19+00:00","headline":"BTCS reduces stockholder quorum requirement from majority to 33.3%","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026548","json":"https://secwatch.observer/filing/0001493152-26-026548.json","markdown":"https://secwatch.observer/filing/0001493152-26-026548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/0001493152-26-026548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/form8-k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"On May 29, 2026, the board of directors of BTCS Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) and adopted an amendment to the quorum requirement contained in Article II, Section 2.9 of the Bylaws (the “Amendment”) to provide that the holders of thirty-three and one third percent (33.3%) of the voting power of the Company entitled to vote at a meeting of stockholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1436229/000149315226026548/0001493152-26-026548-index.htm"}},{"accession":"0001682852-26-000101","ticker":"MRNA","company_name":"Moderna, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000101","json":"https://secwatch.observer/filing/0001682852-26-000101.json","markdown":"https://secwatch.observer/filing/0001682852-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/mrna-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm"}},{"accession":"0001065696-26-000036","ticker":"LKQ","company_name":"LKQ CORP","filed_at":"2026-05-08T23:59:59+00:00","headline":"LKQ stockholders approve 25% special meeting right; all director nominees elected","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001065696-26-000036","json":"https://secwatch.observer/filing/0001065696-26-000036.json","markdown":"https://secwatch.observer/filing/0001065696-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/0001065696-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/lkq-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"the Company’s stockholders, upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment (the “Charter Amendment”) to the Company’s Restated Certificate of Incorporation to provide stockholders holding a combined 25% or more of the Company’s common stock with the right to request a special meeting of stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1065696/000106569626000036/0001065696-26-000036-index.htm"}},{"accession":"0001140361-26-020041","ticker":"ENTG","company_name":"ENTEGRIS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"Entegris shareholders eliminate supermajority voting; all directors elected","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020041","json":"https://secwatch.observer/filing/0001140361-26-020041.json","markdown":"https://secwatch.observer/filing/0001140361-26-020041.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101302/000114036126020041/0001140361-26-020041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101302/000114036126020041/ef20072733_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"On February 5, 2026, the Board approved the adoption of the Amended and Restated By-Laws of the Company to conform to the Second Amended and Restated Certificate of Incorporation. The Board’s approval of the Amended and Restated By-Laws was contingent upon the stockholders’ approval of the Second Amended and Restated Certificate of Incorporation. The Amended and Restated By-Laws became effective on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1101302/000114036126020041/0001140361-26-020041-index.htm"}},{"accession":"0001193125-26-214945","ticker":"MAN","company_name":"ManpowerGroup Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"ManpowerGroup declares $0.72 dividend; shareholders approve equity plan amendment and director removal without cause","event_type":"other_material","sec_items":["5.02","5.03","5.07","8.01","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214945","json":"https://secwatch.observer/filing/0001193125-26-214945.json","markdown":"https://secwatch.observer/filing/0001193125-26-214945.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/0001193125-26-214945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/man-20260508.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"the Board of Directors of the Company amended Section 3.3 of Article III of the Company’s Amended and Restated By-Laws (the “ By-Laws Amendment ”) to permit the removal of a director with or without cause by the affirmative vote of two-thirds of the outstanding shares of capital stock of the Company entitled to vote at a meeting of shareholders duly called for such purpose. The effective date of the By-Laws Amendment is May 8, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/871763/000119312526214945/0001193125-26-214945-index.htm"}},{"accession":"0001477932-26-002848","ticker":"CCTC","company_name":"LataMed AI Corp.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Latamed AI Corp. authorizes 5M shares of Series C Voting Preferred Stock (20 votes/share)","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-002848","json":"https://secwatch.observer/filing/0001477932-26-002848.json","markdown":"https://secwatch.observer/filing/0001477932-26-002848.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477960/000147793226002848/0001477932-26-002848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477960/000147793226002848/cctc_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/0001193125-26-029705-index.htm","comparable_excerpt":"On May 6, 2026, the Board of Directors of LataMed AI Corp. (formerly Catalyst Crew Technologies Corp.) (the “Company”) approved the designation of a new series of preferred stock designated as the “Series C Voting Preferred Stock” and filed a Certificate of Designation with the Nevada Secretary of State establishing the rights, preferences, and limitations of such series.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1477960/000147793226002848/0001477932-26-002848-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}